Ardee Industries Limited’s Initial Public Offering to open on Wednesday, August 05, 2026

Ardee Industries Limited (the “Company”) proposes to open the initial public offering (“Offer”) of its equity shares of face value ₹2 each (“Equity Shares”) on Wednesday, August 05, 2026. The Anchor Investor Bidding Date is a Working Day prior to Bid/Offer Opening Date, being Tuesday, August 04, 2026. The Bid/Offer Closing Date is Friday, August 07, 2026.

The Price Band of the Offer has been fixed from ₹ 50 per Equity Share of face value ₹2 each to ₹53 per Equity Share of face value of ₹2 each. Bids can be made for a minimum of 281 Equity Shares of face value ₹2 each and multiples of 281 Equity Shares of face value ₹2 each thereafter.

The Offer comprises a fresh issue of Equity Shares aggregating up to ₹320 Crores (the “Fresh Issue”) and an Offer for Sale of up to 19,975,000 Equity Shares by certain promoter selling shareholders including up to 9,987,500 Equity Shares of face value ₹2 each by Sandeep Aggarwal and up to 9,987,500 Equity Shares of face value ₹ 2 each by Nikunj Aggarwal (together the “Promoter Selling Shareholders”)

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs” and such portion, the “QIB Portion”), provided that our Company may, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“Anchor Investor Portion”), of which 40% shall be available for allocation as follows, (i) 33.33% shall be available for allocation to domestic Mutual Funds, and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids being received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the price at which allocation is made to Anchor Investors (the “Anchor Investor Allocation Price”). In the event of undersubscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds.

Further, not less than 15% of the Offer shall be available for allocation to Non-Institutional Bidders, of which one-third of the Non-Institutional Portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹ 0.20 million and up to ₹ 1.00 million and two-thirds of the Non-Institutional Portion shall be available for allocation to Non-Institutional Bidders with a Bid size of more than ₹1.00 million provided that under-subscription in either of these two sub-categories of the Non-Institutional Portion may be allocated to Non-Institutional Bidders in the other sub-category of Non-Institutional Portion in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price, and not less than 35% of the Offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount (“ASBA”) process by providing details of their respective ASBA accounts and UPI ID in case of UPI Bidders using the UPI Mechanism (as defined hereinafter)), as applicable, pursuant to which their corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or by the Sponsor Bank(s) under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process.

The Equity Shares are proposed to be listed on BSE Limited (“BSE”) and the National Stock Exchange of India Limited (“NSE”). For the purpose of the Offer, NSE shall be the Designated Stock Exchange.

Comments

Post a Comment

Popular posts from this blog

BPCL Dealer network launches “Fuelling the Festive Spirit” Campaign

Image
  Bharat Petroleum Corporation Limited (BPCL) dealer network has rolled out its festive season campaign, “Fuelling the Festive Spirit”, from 22nd September to 31st October 2025 across 3,000 Retail Outlets in Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu.   Customers fuelling up with eligible transactions can win exciting prizes of 17 car and  83 Bikes through QR-based digital  slogan context participation. BPCL spokesperson said, “Festivals in India are a time of joy, giving, and togetherness. With ‘Fuelling the Festive Spirit,’ we are delighted to reward our customers and empower our frontline teams, making every visit to our retail outlets during this festive season truly memorable.”
Read more

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program

Image
First Private Hospital in India to Successfully Complete CAR T Cell Therapy.  In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to Made in India CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.   Marking a historic moment in the country's medical landscape , Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.   CAR-T cell therapies, often known as living drugs involve the extraction of a patients T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are t...
Read more

Gleneagles Hospital Successfully Treats Rare CNS (Brain) Lymphoma with Advanced CAR-T Cell Therapy

Image
Gleneagles Hospital Chennai, a part of Fortis Healthcare, has successfully treated a 49-year-old patient from Andhra Pradesh diagnosed with a rare and aggressive form of CNS(brain) lymphoma using advanced CAR-T cell therapy. Despite developing multiple serious treatment-related complications, the patient achieved complete remission and is doing well. The patient presented with complaints of persistent headache, giddiness, difficulty in walking, and weakness in his left arm and leg. Detailed investigations confirmed Primary Central Nervous System Lymphoma (PCNSL) , a rare type of lymphoma that affects the brain and is known to be difficult to treat. The patient initially received high-dose chemotherapy, the standard first-line treatment for this condition. However, the disease continued to progress despite four cycles of treatment. He subsequently underwent radiotherapy with chemotherapy, followed by oral targeted therapy as bridging treatment. As the lymphoma remained resistant to ...
Read more